A

Alpine Clinical Research Center | Boulder, CO

Research site
(Unclaimed)
Location
3434 47th Street, Suite 201, Boulder, Colorado, United States of America

Site insights

Top conditions

Top treatments

Atogepant
Bapineuzumab
ABBV-951
Lasmiditan
Pitolisant
Peramivir
Galcanezumab
NRP104
(R)-2-amino-3-phenylpropylcarbamate Hydrochloride
Carbidopa

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 51 total trials

A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia

The primary objective of this study is to assess the long-term safety and effectiveness of pitolisant in patients with idiopathic hypersomnia (IH) wh...

Active, not recruiting
Idiopathic Hypersomnia
Excessive Daytime Sleepiness
Drug: Pitolisant

This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic o...

Active, not recruiting
Chronic Migraine
Episodic Migraine
Drug: Atogepant 60 mg

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's d...

Enrolling
Alzheimer's Disease
Drug: Remternetug (SC)
Drug: Placebo

The primary purpose of this study is to evaluate the efficacy of ACU193 infusions administered once every four weeks (Q4W) in slowing cognitive and f...

Enrolling
Alzheimer Disease
Drug: ACU193
Drug: Placebo

This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab (SAR440340)

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)

Enrolling
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Remibrutinib

The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have particip...

Enrolling
Relapsing Multiple Sclerosis
Biological: 13-valent pneumococcal conjugate vaccine (13-PCV)
Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obs...

Active, not recruiting
OSA
Drug: Placebo
Drug: AD109

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot fr...

Active, not recruiting
Parkinson's Disease (PD)
Drug: ABBV-951

Primary Objective:Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab SAR440340

Trial sponsors

Lilly logo
Allergan logo
Pfizer logo
AbbVie logo
J
Jazz Pharmaceuticals logo
BioCryst logo
D
H
N

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems